496 related articles for article (PubMed ID: 25132742)
1. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy.
Han LL; Lv Y; Guo H; Ruan ZP; Nan KJ
World J Gastroenterol; 2014 Aug; 20(30):10249-61. PubMed ID: 25132742
[TBL] [Abstract][Full Text] [Related]
2. Emerging targeted strategies in advanced hepatocellular carcinoma.
Finn RS
Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeted therapy for hepatocellular carcinoma: current and future.
Shin JW; Chung YH
World J Gastroenterol; 2013 Oct; 19(37):6144-55. PubMed ID: 24115810
[TBL] [Abstract][Full Text] [Related]
5. The significance of exosomes in the development and treatment of hepatocellular carcinoma.
Li X; Li C; Zhang L; Wu M; Cao K; Jiang F; Chen D; Li N; Li W
Mol Cancer; 2020 Jan; 19(1):1. PubMed ID: 31901224
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
7. The Expression and Function of Circadian Rhythm Genes in Hepatocellular Carcinoma.
Jiang Y; Shen X; Fasae MB; Zhi F; Chai L; Ou Y; Feng H; Liu S; Liu Y; Yang S
Oxid Med Cell Longev; 2021; 2021():4044606. PubMed ID: 34697563
[TBL] [Abstract][Full Text] [Related]
8. Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.
Scaggiante B; Kazemi M; Pozzato G; Dapas B; Farra R; Grassi M; Zanconati F; Grassi G
World J Gastroenterol; 2014 Feb; 20(5):1268-88. PubMed ID: 24574801
[TBL] [Abstract][Full Text] [Related]
9. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation-related Diagnostic and Therapeutic Drug Target Markers in Hepatocellular Carcinoma.
Watson ME; Diepeveen LA; Stubbs KA; Yeoh GC
J Gastrointestin Liver Dis; 2015 Sep; 24(3):349-57. PubMed ID: 26405707
[TBL] [Abstract][Full Text] [Related]
12. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
14. Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma.
Yao M; Wang L; Qiu L; Qian Q; Yao D
Anticancer Agents Med Chem; 2015; 15(4):453-60. PubMed ID: 25511513
[TBL] [Abstract][Full Text] [Related]
15. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
[TBL] [Abstract][Full Text] [Related]
16. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
17. Exosomal microRNAs as Biomarkers and Therapeutic Targets for Hepatocellular Carcinoma.
Sorop A; Constantinescu D; Cojocaru F; Dinischiotu A; Cucu D; Dima SO
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066780
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect.
Wang Z; Zhang G; Wu J; Jia M
Drug Discov Ther; 2013 Aug; 7(4):137-43. PubMed ID: 24071575
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.
Cai S; Bai Y; Wang H; Zhao Z; Ding X; Zhang H; Zhang X; Liu Y; Jia Y; Li Y; Chen S; Zhou H; Liu H; Yang C; Sun T
J Exp Clin Cancer Res; 2020 Jul; 39(1):135. PubMed ID: 32669125
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
